Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes - Preclinical biology and mechanisms of action

被引：310

作者：

Drucker, Daniel J. ^{[1
]}

机构：

[1] Univ Toronto, Mt Sinai Hosp, Dept Med, Samuel Lunenfeld Res Inst,Banting & Best Diabet C, Toronto, ON M5G 1X5, Canada

来源：

DIABETES CARE | 2007年 / 30卷 / 06期

关键词：

D O I：

10.2337/dc07-0228

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1335 / 1343

页数：9

共 84 条

[1] GENOMIC ORGANIZATION, EXACT LOCALIZATION, AND TISSUE EXPRESSION OF THE HUMAN CD26 (DIPEPTIDYL PEPTIDASE-IV) GENE [J].

ABBOTT, CA ;

BAKER, E ;

SUTHERLAND, GR ;

MCCAUGHAN, GW .

IMMUNOGENETICS, 1994, 40 (05) :331-338

[2] Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice [J].

Ahrén, B ;

Holst, JJ ;

Mårtensson, H ;

Balkan, B .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 404 (1-2) :239-245

[3] Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice [J].

Ahrén, B ;

Hughes, TE .

ENDOCRINOLOGY, 2005, 146 (04) :2055-2059

[4]

Aytac U, 2001, CANCER RES, V61, P7204

[5]

Aytac Ugur, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P11, DOI 10.2174/1568008043340035

[6] Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats [J].

Balkan, B ;

Kwasnik, L ;

Miserendino, R ;

Holst, JJ ;

Li, X .

DIABETOLOGIA, 1999, 42 (11) :1324-1331

[7] Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers [J].

Bergman, AJ ;

Stevens, C ;

Zhou, YY ;

Yi, BM ;

Laethem, M ;

De Smet, M ;

Snyder, K ;

Hilliard, D ;

Tanaka, W ;

Zeng, W ;

Tanen, M ;

Wang, AQ ;

Chen, L ;

Winchell, G ;

Davies, MJ ;

Ramael, S ;

Wagner, JA ;

Herman, GA .

CLINICAL THERAPEUTICS, 2006, 28 (01) :55-72

[8] Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer [J].

Busek, P ;

Malík, R ;

Sedo, A .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (03) :408-421

[9] Circulating CD26 is negatively associated with inflammation in human and experimental arthritis [J].

Busso, N ;

Wagtmann, N ;

Herling, C ;

Chobaz-Péclat, V ;

Bischof-Delaloye, A ;

So, A ;

Grouzmann, E .

AMERICAN JOURNAL OF PATHOLOGY, 2005, 166 (02) :433-442

[10] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J].

Charbonnel, Bernard ;

Karasik, Avraham ;

Liu, Ji ;

Wu, Mei ;

Meininger, Gary .

DIABETES CARE, 2006, 29 (12) :2638-2643

← 1 2 3 4 5 6 7 8 9 →